Teva Pharma (TEVA) Reports In-Line Q1 EPS; Narrows Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Teva Reports First Quarter 2022 Financial Results
May 3, 2022 7:00 AM EDTRevenues of $3.7 billion GAAP diluted loss per share of $0.86 Non-GAAP diluted EPS of $0.55 Cash flow used in operating activities of $49 million Free cash flow of $117 million 2022 revenue outlook revised lower to reflect ongoing impact of foreign exchange fluctuations; COPAXONE® outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations; all other key components reaffirmed: Revenues of $15.4 - $16.0 billion vs. previous range of $15.6 - $16.2 billion COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million Adjusted EBITDA of $4.7 - $5.0... More
